Director, Market Access Western Europe Region

About BridgeBio Pharma, Inc.  BridgeBio is a biopharmaceutical company dedicated to discovering, developing, and delivering transformative medicines for patients living with genetic diseases and genetically defined cancers. Since our founding in 2015, we have built a diverse portfolio of more than 20 drug development programs, ranging from early discovery to late-stage clinical trials, across multiple therapeutic areas including precision oncology, cardiology, endocrinology, neurology, and renal disease.

We have already achieved regulatory approval for three therapies and continue to advance promising science from academia into meaningful treatments for patients worldwide.  Who We Are  BridgeBio is a global biotechnology company with our Global Headquarters located in San Francisco, USA, and our International HQ located in Zug, Switzerland.

Since establishing our European presence in 2021, we’ve been building empowered, high-performing teams across countries — with experienced colleagues who move quickly, take ownership, and are fuelling the company’s international growth.  At BridgeBio, you’ll find an energetic and collaborative culture where pragmatism meets bold decision-making.

We embrace uncertainty with confidence, guided by our commitment to making a meaningful impact for patients. Our people are trusted and empowered, united by urgency, purpose, and the drive to advance science for patients around the world.  To learn more about our story and company culture, visit us at https://bridgebio.com What You'll Do This critical role reporting to the regional General Manager - WEU, requires you to be a driven individual with a track record in navigating in the medico-economic environment, securing reimbursement, pricing & patient access to medicines in France (as a priority), Belgium, and the Netherlands.  Establish effective collaboration and communication with external stakeholders, such as healthcare professionals, payers, policy makers including representing BridgeBio and leading and/ or actively participating in HTA and pricing meetings, and the medico-economic community events is also critical.

Your primary role will be to design, anticipate and drive all steps of the HTA, pricing and reimbursement process within each country and to engage with early scientific advice and early access programs where & when needed.  You will, therefore, be able to operate in a fast-paced, sometimes ambiguous environment where you will influence without authority and effectively communicate WEU market access strategies to all levels.  Responsibilities The responsibilities below give the general nature and level of work but are not intended to be an exhaustive list of activities, duties, and responsibilities required. Therefore, you will be expected to perform all other duties as assigned or required.  HTA, Pricing & Reimbursement  Lead internal and external stakeholders to develop and execute a strategy to demonstrate the value of BridgeBio’s medicines to French, Belgian & Dutch HTA bodies/payers to ensure pricing, reimbursement and optimal patient access Responsible for all steps during the value assessments & pricing negotiations, i.e. evidence generation, KOL/expert support, advocacy, assessment analysis, written statements, oral hearing, pricing negotiation, and arbitration Ensure timely reimbursement, including developing necessary processes, forms and administrative steps for actual availability and access of BridgeBio drugs in the market Create and develop a strong trust relationship with key external stakeholders and decision makers, to be perceived as a partner and an advocate for patients’ access Develop and implement early access solutions for France (mainly) and Belgium / Netherlands Clinical development  Influence clinical development plans to incorporate important endpoints and design features into clinical trials that satisfy French / WEU HTA and payers needs  Evidence generation  Assess WEU region needs related to specific diseases and pipeline assets and develop and execute research programs to prepare the necessary data packages for use in HTA assessments and pricing negotiations.  Evaluate and propose RWE and data to support access, funding, adoption and commercial success of the drugs Other  Interact effectively with patients’ groups, healthcare professionals, policy makers and payers to understand the burden of diseases that are the target of BridgeBio products Lead the shaping and execution of health technology assessment (HTA) early scientific advice engagement Assess the viability of early access programs in the region and work with internal/external stakeholders to implement them Effectively execute against market access plan within budget Manage external suppliers to develop, adapt and validate HTA deliverables (e.g., systematic literature reviews, indirect & mixed treatment comparisons, health economic models, and submission documents) Support the WEU teams with developing and implementing innovative value materials and tools for use by their field teams to demonstrate the products' value proposition and encourage reimbursed medicines' uptake Develop and maintain a network of key national & regional access, HEOR & academic leaders The above job description documents the general nature and level of work but is not intended to be an exhaustive list of activities, duties, and responsibilities required of job incumbents.

Therefore, job incumbents are expected to perform all other duties as assigned or required, as training and experience allow.  Where You'll Work This is a France-based role with a significant stakeholders’ facing component. We anticipate travel within France as a priority country for meetings with policy makers, payers, and conferences attendance, Belgium, the Netherlands (and Switzerland for internal alignment and engagement at our international office in Zug) and European travel for conferences and events (internal and external).

Local team meetings and designated office location in France is Paris.  Who You Are At least 5 - 7 years leading HTA submissions, HEOR projects, pricing negotiations and policy makers advocacy in France  Knowledge and experience in Belgium and the Netherlands will be a strong plus  Profound knowledge of the French (and Benelux) healthcare systems & regulations  Experience in successfully influencing clinical trial design Experience in generating relevant data for HTA submission, HEOR & pricing negotiations Experience in presenting at senior levels & to external thought leaders Proven experience in project management of multidisciplinary teams (including external providers) Experience in launching orphan / ultra-orphan drugs Fluent in verbal and written French and English Demonstrated ability to organize and execute plans against objectives in a semi-autonomous environment while working effectively in a cross-functional team environment Knowledge of product commercialization processes Highly accountable and self-disciplined leader with a sense of responsibility and ownership of projects and products  Rewarding Those Who Make the Mission Possible We have high expectations for our team members.

We make sure those working hard for patients are rewarded and cared for in return.   Market leading compensation Hybrid work model - we value your flexibility in how you work, but encourage time in the office to strengthen our culture, collaboration, and sense of community We provide career development through regular feedback, continuous education and professional development programs We celebrate strong performance with financial rewards, peer-to-peer recognition, and growth opportunities

BridgeBio Pharma (NASDAQ: BBIO) is a biopharmaceutical company dedicated to advancing a diverse pipeline of medicines that target genetic diseases. Founded in 2015, BridgeBio is committed to developing innovative therapies that address unmet medical needs in various rare and genetic diseases. With a focus on precision medicine and a patient-centered approach, BridgeBio is at the forefront of revolutionizing treatment options for individuals affected by genetic disorders.